Accelerated ageing in young sickle cell patients linked to elevated T-cell p16INK4a

Researchers have discovered that young people with sickle cell disease (SCD) exhibit signs of accelerated biological ageing compared to those without the disease.

By measuring levels of p16INK4a, a key marker of cellular ageing, the team found significantly higher levels in individuals with SCD. Remarkably, some participants showed biological ageing equivalent to an additional 43 years.

These findings suggest that SCD may drive faster ageing in the body, offering new insights into the disease’s long-term impact.

Sickle cell disease (SCD) is a genetic condition primarily affecting individuals of African or Mediterranean descent. While treatments have advanced, people with SCD often face significant health challenges, including complications that mimic the effects of ageing.

Cellular ageing, or senescence, occurs when cells stop dividing yet continue to send harmful signals that damage surrounding tissues. Researchers believe this process happens at an accelerated rate in people with SCD, underscoring the importance of finding ways to slow it down and mitigate its impact.

The study compared p16INK4a levels in 18 adolescents and young adults with SCD to 27 healthy people of the same age. The results showed that even the youngest participant with SCD had higher levels of this ageing marker than anyone in the non-SCD group.

“Our youngest participant, a 15-year-old with SCD, had a higher p16 expression than all the comparators, underscoring the early rise of p16 expression in this population.”

The researchers believe this faster ageing could be caused by the chronic inflammation, lack of oxygen, and stress on the body associated with SCD. Along with managing the symptoms of the disease, SCD patients also face a higher risk of ageeing-related problems like organ damage and physical decline much earlier in life.

The findings suggest that measuring p16INK4a levels could help clinicians identify patients at risk for these problems earlier and offer targeted care. The study also opens the door to new treatments, such as drugs that aim to remove old, damaged cells. These therapies could potentially slow down the ageing process.

Further research is essential to confirm these findings and to gain a deeper understanding of how to support SCD patients effectively. Larger, long-term studies could investigate whether therapies targeting cell ageing can help prevent complications and improve the quality of life for individuals with SCD.

In conclusion, this study marks an important step in understanding how SCD accelerates ageing and offers new ways to improve the lives of those living with the condition.